Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets14-03-2022
14-03-2022
Zydus Lifesciences Ltd - 532321 - USFDA Inspection
We hereby inform that the USFDA inspected the Company's injectable facility at Jarod, Gujarat from 24th February to 10th March, 2022. At the end of the inspection, three observations are issued.10-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated March 9, 2022 titled 'Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets'.09-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY(tm) (Fosdenopterin)08-03-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD)07-03-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Intimation of revised MOA and AOA of the Company, pursuant to change in the name of the Company.28-02-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Notice of name change of the Company25-02-2022
Cadila Healthcare changes name to Zydus Lifesciences Limited
Unveils 'innovation and care' centric corporate brand identity24-02-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Change of Company Name
Name of the Company is changed from Cadila Healthcare Limited to Zydus Lifesciences Limited.24-02-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated February 23, 2022 titled 'Zydus receives final approval from USFDA for Dapagliflozin Tablets'23-02-2022